Stage III Breast Cancer AJCC v7
Information
- Disease name
- Stage III Breast Cancer AJCC v7
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03101748 | Active, not recruiting | Phase 1/Phase 2 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | January 29, 2018 | January 1, 2026 |
| NCT01463072 | Active, not recruiting | Phase 2 | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer | June 19, 2012 | December 30, 2024 |
| NCT03199885 | Active, not recruiting | Phase 3 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | April 5, 2019 | May 15, 2025 |
| NCT03281902 | Active, not recruiting | Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy | November 13, 2017 | December 1, 2024 | |
| NCT01552434 | Active, not recruiting | Phase 1 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | March 16, 2012 | March 31, 2026 |
| NCT01638533 | Active, not recruiting | Phase 1 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | June 12, 2012 | March 5, 2025 |
| NCT02079662 | Active, not recruiting | N/A | The Role of Lifestyle Factors in Breast Cancer-Related Outcomes | June 13, 2013 | December 31, 2025 |
| NCT04054557 | Active, not recruiting | N/A | Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence | July 31, 2019 | January 31, 2025 |
| NCT02311933 | Active, not recruiting | Phase 2 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | May 28, 2015 | February 4, 2025 |
| NCT03317405 | Active, not recruiting | Phase 1 | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | October 31, 2018 | August 1, 2024 |
| NCT02498613 | Active, not recruiting | Phase 2 | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | August 31, 2016 | April 10, 2025 |
| NCT02593175 | Active, not recruiting | Phase 2 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | August 26, 2016 | August 31, 2025 |
| NCT00496795 | Active, not recruiting | Phase 2 | Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer | September 2007 | May 2026 |
| NCT02754752 | Active, not recruiting | Phase 2 | Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment | September 13, 2016 | December 31, 2024 |
| NCT02883062 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | August 2, 2017 | January 23, 2025 |
| NCT02954874 | Active, not recruiting | Phase 3 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | January 18, 2017 | May 31, 2026 |
| NCT03012100 | Active, not recruiting | Phase 2 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | March 31, 2017 | July 31, 2026 |
| NCT00576654 | Active, not recruiting | Phase 1 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | December 5, 2007 | June 30, 2023 |
| NCT00376688 | Completed | Phase 2 | Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer | July 11, 2006 | December 16, 2019 |
| NCT02689427 | Completed | Phase 2 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | September 22, 2016 | November 15, 2023 |
| NCT03094052 | Completed | Phase 2 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | October 9, 2018 | October 31, 2022 |
| NCT03106415 | Completed | Phase 1/Phase 2 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | September 27, 2017 | May 19, 2022 |
| NCT03407716 | Completed | Early Phase 1 | Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors | March 1, 2019 | February 22, 2021 |
| NCT03411070 | Completed | Early Phase 1 | SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer | April 7, 2019 | December 6, 2021 |
| NCT03872388 | Completed | Phase 2 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | January 14, 2019 | October 19, 2023 |
| NCT04197687 | Recruiting | Phase 2 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | February 20, 2020 | January 15, 2025 |
| NCT03428802 | Recruiting | Phase 2 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | March 8, 2018 | October 2, 2023 |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT02276443 | Recruiting | N/A | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | November 9, 2015 | November 30, 2026 |
| NCT02474173 | Terminated | Phase 1 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | January 15, 2016 | October 26, 2022 |
| NCT03326258 | Withdrawn | Phase 1/Phase 2 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | April 20, 2018 | April 20, 2018 |